Citrulline and anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis

By Yamada Ryo   Suzuki Akari   Yamamoto Kazuhiko  

Future Rheumatology, Vol. 1, Iss. 2, 2006-04 ,pp. : 249-258

Future Medicine

Access to resources Recommend Favorite

Sustained improvement of vascular endothelial function during anti-TNFα treatment in rheumatoid arthritis patients

By Sidiropoulos P. I.   Siakka P.   Pagonidis K.   Raptopoulou A.   Kritikos H.   Tsetis D.   Boumpas D. T.  

Scandinavian Journal of Rheumatology, Vol. 38, Iss. 1, 2009-01 ,pp. : 6-10

Informa Healthcare

Access to resources Recommend Favorite

Insulin resistance in patients with rheumatoid arthritis: effect of anti-TNFα therapy

By Rosenvinge A.   Krogh-Madsen R.   Baslund B.   Pedersen B. K.  

Scandinavian Journal of Rheumatology, Vol. 36, Iss. 2, 2007-01 ,pp. : 91-96

Informa Healthcare

Access to resources Recommend Favorite

Prevalence and predictive value of anti-cyclic citrullinated protein antibodies for future development of rheumatoid arthritis in early undifferentiated arthritis

By Emad Yasser   Shehata Mohamed   Ragab Yasser   Saad Ahmed   Hamza Hosny   Abou-Zeid Alaa  

Modern Rheumatology, Vol. 20, Iss. 4, 2010-08 ,pp. : 358-365

Springer Publishing Company

Access to resources Recommend Favorite

Second generation anti-cyclic citrullinated peptide (anti-CCP2) antibodies can replace other anti-filaggrin antibodies and improve rheumatoid arthritis diagnosis

By Grootenboer-Mignot S   Nicaise-Roland P   Delaunay C   Meyer O   Chollet-Martin S   Labarre C  

Scandinavian Journal of Rheumatology, Vol. 33, Iss. 4, 2004-07 ,pp. : 218-220

Informa Healthcare

Access to resources Recommend Favorite